Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma

Glenn J. Hanna, Vishwajith Sridharan, Danielle N. Margalit, Stephanie K. La Follette, Nicole G. Chau, Guilherme Rabinowits, Jochen H. Lorch, Robert I. Haddad, Roy B. Tishler, Karen Anderson, Jonathan D. Schoenfeld

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

BACKGROUND: HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) is increasing in incidence. Laboratory assays that identify virally-mediated disease and predict HPV clearance in OPSCC may have important prognostic implications. OBJECTIVE: Here we investigated serum, salivary HPV16 early (E) antibodies before and after definitive chemoradiotherapy (CRT) in patients with locoregionally advanced OPSCC. METHODS: We prospectively measured salivary, serum samples at the beginning of and 6-7 weeks following the completion of CRT in 44 patients. IgG antibodies targeting N- and C-terminal fragments of E2 (NE2, CE2), E6 and E7 were measured by programmable enzyme-linked immunosorbent assay. RESULTS:We observed serum antibodies directed against HPV-associated E proteins in patients with HPV-associated OPSCC. E7 directed antibodies were detected in saliva in the majority of patients, and were associated with HPV status (p = 0.03).When analyzed longitudinally, median salivary E7 antibody levels decreased significantly post-treatment (p = 0.007). CONCLUSIONS: Our results demonstrate the feasibility of measuring HPV16 E antibodies in saliva and serum. E7 antibodies, in particular, are more detectable in saliva as compared with other E protein antibodies. Measuring E7 salivary antibody levels at various time points may have utility in understanding HPV clearance and should be explored for their ability to predict the risk of recurrence.

Original languageEnglish (US)
Pages (from-to)129-136
Number of pages8
JournalCancer Biomarkers
Volume19
Issue number2
DOIs
StatePublished - 2017

Fingerprint

Squamous Cell Carcinoma
Antibodies
Serum
Saliva
Therapeutics
Chemoradiotherapy
Proteins
Immunoglobulin G
Enzyme-Linked Immunosorbent Assay
Recurrence
Incidence

Keywords

  • antibodies
  • HPV
  • oropharyngeal cancer
  • saliva

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Hanna, G. J., Sridharan, V., Margalit, D. N., La Follette, S. K., Chau, N. G., Rabinowits, G., ... Schoenfeld, J. D. (2017). Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. Cancer Biomarkers, 19(2), 129-136. https://doi.org/10.3233/CBM-160071

Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. / Hanna, Glenn J.; Sridharan, Vishwajith; Margalit, Danielle N.; La Follette, Stephanie K.; Chau, Nicole G.; Rabinowits, Guilherme; Lorch, Jochen H.; Haddad, Robert I.; Tishler, Roy B.; Anderson, Karen; Schoenfeld, Jonathan D.

In: Cancer Biomarkers, Vol. 19, No. 2, 2017, p. 129-136.

Research output: Contribution to journalArticle

Hanna, GJ, Sridharan, V, Margalit, DN, La Follette, SK, Chau, NG, Rabinowits, G, Lorch, JH, Haddad, RI, Tishler, RB, Anderson, K & Schoenfeld, JD 2017, 'Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma', Cancer Biomarkers, vol. 19, no. 2, pp. 129-136. https://doi.org/10.3233/CBM-160071
Hanna, Glenn J. ; Sridharan, Vishwajith ; Margalit, Danielle N. ; La Follette, Stephanie K. ; Chau, Nicole G. ; Rabinowits, Guilherme ; Lorch, Jochen H. ; Haddad, Robert I. ; Tishler, Roy B. ; Anderson, Karen ; Schoenfeld, Jonathan D. / Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. In: Cancer Biomarkers. 2017 ; Vol. 19, No. 2. pp. 129-136.
@article{85f751937e76418cbec21a58da6caa52,
title = "Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma",
abstract = "BACKGROUND: HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) is increasing in incidence. Laboratory assays that identify virally-mediated disease and predict HPV clearance in OPSCC may have important prognostic implications. OBJECTIVE: Here we investigated serum, salivary HPV16 early (E) antibodies before and after definitive chemoradiotherapy (CRT) in patients with locoregionally advanced OPSCC. METHODS: We prospectively measured salivary, serum samples at the beginning of and 6-7 weeks following the completion of CRT in 44 patients. IgG antibodies targeting N- and C-terminal fragments of E2 (NE2, CE2), E6 and E7 were measured by programmable enzyme-linked immunosorbent assay. RESULTS:We observed serum antibodies directed against HPV-associated E proteins in patients with HPV-associated OPSCC. E7 directed antibodies were detected in saliva in the majority of patients, and were associated with HPV status (p = 0.03).When analyzed longitudinally, median salivary E7 antibody levels decreased significantly post-treatment (p = 0.007). CONCLUSIONS: Our results demonstrate the feasibility of measuring HPV16 E antibodies in saliva and serum. E7 antibodies, in particular, are more detectable in saliva as compared with other E protein antibodies. Measuring E7 salivary antibody levels at various time points may have utility in understanding HPV clearance and should be explored for their ability to predict the risk of recurrence.",
keywords = "antibodies, HPV, oropharyngeal cancer, saliva",
author = "Hanna, {Glenn J.} and Vishwajith Sridharan and Margalit, {Danielle N.} and {La Follette}, {Stephanie K.} and Chau, {Nicole G.} and Guilherme Rabinowits and Lorch, {Jochen H.} and Haddad, {Robert I.} and Tishler, {Roy B.} and Karen Anderson and Schoenfeld, {Jonathan D.}",
year = "2017",
doi = "10.3233/CBM-160071",
language = "English (US)",
volume = "19",
pages = "129--136",
journal = "Cancer Biomarkers",
issn = "1574-0153",
publisher = "IOS Press",
number = "2",

}

TY - JOUR

T1 - Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma

AU - Hanna, Glenn J.

AU - Sridharan, Vishwajith

AU - Margalit, Danielle N.

AU - La Follette, Stephanie K.

AU - Chau, Nicole G.

AU - Rabinowits, Guilherme

AU - Lorch, Jochen H.

AU - Haddad, Robert I.

AU - Tishler, Roy B.

AU - Anderson, Karen

AU - Schoenfeld, Jonathan D.

PY - 2017

Y1 - 2017

N2 - BACKGROUND: HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) is increasing in incidence. Laboratory assays that identify virally-mediated disease and predict HPV clearance in OPSCC may have important prognostic implications. OBJECTIVE: Here we investigated serum, salivary HPV16 early (E) antibodies before and after definitive chemoradiotherapy (CRT) in patients with locoregionally advanced OPSCC. METHODS: We prospectively measured salivary, serum samples at the beginning of and 6-7 weeks following the completion of CRT in 44 patients. IgG antibodies targeting N- and C-terminal fragments of E2 (NE2, CE2), E6 and E7 were measured by programmable enzyme-linked immunosorbent assay. RESULTS:We observed serum antibodies directed against HPV-associated E proteins in patients with HPV-associated OPSCC. E7 directed antibodies were detected in saliva in the majority of patients, and were associated with HPV status (p = 0.03).When analyzed longitudinally, median salivary E7 antibody levels decreased significantly post-treatment (p = 0.007). CONCLUSIONS: Our results demonstrate the feasibility of measuring HPV16 E antibodies in saliva and serum. E7 antibodies, in particular, are more detectable in saliva as compared with other E protein antibodies. Measuring E7 salivary antibody levels at various time points may have utility in understanding HPV clearance and should be explored for their ability to predict the risk of recurrence.

AB - BACKGROUND: HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) is increasing in incidence. Laboratory assays that identify virally-mediated disease and predict HPV clearance in OPSCC may have important prognostic implications. OBJECTIVE: Here we investigated serum, salivary HPV16 early (E) antibodies before and after definitive chemoradiotherapy (CRT) in patients with locoregionally advanced OPSCC. METHODS: We prospectively measured salivary, serum samples at the beginning of and 6-7 weeks following the completion of CRT in 44 patients. IgG antibodies targeting N- and C-terminal fragments of E2 (NE2, CE2), E6 and E7 were measured by programmable enzyme-linked immunosorbent assay. RESULTS:We observed serum antibodies directed against HPV-associated E proteins in patients with HPV-associated OPSCC. E7 directed antibodies were detected in saliva in the majority of patients, and were associated with HPV status (p = 0.03).When analyzed longitudinally, median salivary E7 antibody levels decreased significantly post-treatment (p = 0.007). CONCLUSIONS: Our results demonstrate the feasibility of measuring HPV16 E antibodies in saliva and serum. E7 antibodies, in particular, are more detectable in saliva as compared with other E protein antibodies. Measuring E7 salivary antibody levels at various time points may have utility in understanding HPV clearance and should be explored for their ability to predict the risk of recurrence.

KW - antibodies

KW - HPV

KW - oropharyngeal cancer

KW - saliva

UR - http://www.scopus.com/inward/record.url?scp=85020962747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020962747&partnerID=8YFLogxK

U2 - 10.3233/CBM-160071

DO - 10.3233/CBM-160071

M3 - Article

C2 - 28387659

AN - SCOPUS:85020962747

VL - 19

SP - 129

EP - 136

JO - Cancer Biomarkers

JF - Cancer Biomarkers

SN - 1574-0153

IS - 2

ER -